Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials

Kairos Pharma, LTD.

Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.
Kairos to pay $900,000 for PreCheck's lab services using SolidTumorCheck+ platform.
PreCheck will develop a companion diagnostic (three-gene PCR) for ENV105 to identify responsive patients.
Target indications: EGFR-driven lung cancer resistant to osimertinib and castrate-resistant prostate cancer.
Companion diagnostic to be submitted for FDA approval to guide Phase 3 patient selection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.